Generic Name and Formulations:
Atovaquone 750mg/5mL; oral susp; citrus flavor.
Indications for MEPRON:
Treatment of mild-to-moderate Pneumocystis jirovecii pneumonia (PCP) in patients intolerant to trimethoprim/sulfamethoxazole (TMP/SMX). Prevention of PCP in patients intolerant to TMP/SMX.
Limitations Of use:
Treatment of more severe PCP has not been studied. Mepron's efficacy has not been studied in those who are failing therapy with TMP/SMX.
Take with food. ≥13yrs: Treatment: 750mg twice daily for 21 days. Prophylaxis: 1500mg once daily.
<13yrs: not established.
GI disorders or inability to take with food. Monitor in severe hepatic impairment. Elderly. Pregnancy (Cat.C). Nursing mothers.
Concomitant rifampin or rifabutin: not recommended. Antagonized by tetracycline; caution and monitor if use is needed. May be antagonized by metoclopramide (use only if other antiemetics are not available). Antagonizes indinavir; caution and monitor if use is needed.
Diarrhea, rash, headache, nausea, fever, rhinitis, vomiting, sweating, flu syndrome, sinusitis, pruritus, insomnia, depression, myalgia.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Immune Checkpoint Inhibitors for NSCLC: Current and Future Approaches
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Erdafitinib Granted FDA Breakthrough Therapy Designation for Urothelial Carcinoma
- NSCLC: Stratifying Patients With Complex EGFR Mutations
- Confronting Racial Disparities in Prostate Cancer Survival Outcomes
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- NSCLC: Pretreatment Weight Loss May Be Linked to Socioeconomic Status
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC